Feature | July 02, 2014 | Melinda Taschetta-Millane

Trends from SNMMI 2014

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) recently held its annual meeting in St. Louis. It provided an in-depth review of molecular imaging technologies, clinical applications, and translational and advanced research topics for molecular imaging professionals — nuclear medicine physicians, scientists, radiologists, cardiologists, pharmacists, technologists, researchers, and others involved and interested in nuclear medicine and molecular imaging and therapy.

On the show floor, several vendors introduced new PET/CT systems for the market. 

Among them was Philips’ Vereos, which is the first on the market to offer digital PET detectors, and offers greater image clarity over traditional analog photomultipliers. 

Toshiba announced the release of its Celesteion system. It currently is pending 510(k) clearance from the U.S. Food and Drug Administration (FDA), and combines high-performance PET and CT for all radiation and oncology imaging needs, including tumor detection, treatment evaluation and CT simulation.

In addition, GE Healthcare introduced its Discovery IQ PET/CT system. It enables both high image quality and intelligent quantitation. It is pending 510(k) clearance from the FDA and not available for sale in the United States. 

You can learn more about the trends and technology showcased at SNMMI 2014 by viewing the videos Editor’s Choice of Most Innovative Technology at SNMMI 2014” and “SNMMI: Trends and New Technology in Nuclear Imaging.” 

Several interesting studies came out of the show, as well, and covered a vast spectrum of topics, including:

• Antibody-based molecular imaging agent hones in on newly targeted cell receptor that 

hints at more aggressive breast cancers and potential therapy;

• Molecular neuroimaging shows a strong association between a sleep disorder and the development of progressive brain diseases such as Parkinson’s;

• Study finds the newest hybrid cardiac molecular imaging system highly effective for the detection of coronary arterial disease;

• Molecular imaging study suggests late-life depression and beta-amyloid plaque in the brain could tip-off hastened development of deadly dementia;

• Researchers can now use radioluminescence to examine the characteristics of single, unconnected cells, and the result is a fascinating picture of diversity among cells previously assumed to behave the same; and

• Wide range of molecular imaging modalities is at researchers’ fingertips with a hybrid device dedicated for early-stage clinical trials.

As always, you can read more about these innovative studies, as well as other industry news, at www.itnonline.com

Related Content

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Overlay Init